Gedeon Richter, PregLem deal
Gedeon acquired women's reproductive health company PregLem for CHF150 million ($153.8 million) in cash and up to CHF295 million ($302.4 million) in potential milestones. Richter said it will commit CHF100 million ($102.5 million) over the next three years to develop and commercialize PregLem's pipeline, which Richter said will complement its existing women's health portfolio.
PregLem's Esmya ulipristal ( PGL4001) is in Phase III testing to treat uterine myoma, with an MAA submission expected this quarter. PregLem has European rights to the selective progesterone receptor modulator (SPRM) to treat gynecological indications, excluding contraception, from HRA Pharma S.A. (Paris, France), as well as North American rights to the compound for benign gynecological disorders (see BioCentury, Dec. 10, 2007 & April 26, 2010). ...